Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

David E. Avigan, M.D.

Co-Author

This page shows the publications co-authored by David Avigan and Robin Joyce.
Connection Strength

2.518
  1. A phase I-II study of rituximab, ifosfamide, mitoxantrone and etoposide (R-IME) for B cell non-Hodgkin's lymphoma prior to and after high-dose chemotherapy and autologous stem cell transplantation (HDC-ASCT). Ann Oncol. 2003; 14 Suppl 1:i21-7.
    View in: PubMed
    Score: 0.262
  2. Rituximab and ifosfamide, mitoxantrone, etoposide (RIME) with Neupogen support for B-cell non-Hodgkin's lymphoma prior to high-dose chemotherapy with autologous haematopoietic transplant. Eur J Haematol Suppl. 2001 Jul; 64:56-62.
    View in: PubMed
    Score: 0.236
  3. MUC1-mediated induction of myeloid-derived suppressor cells in patients with acute myeloid leukemia. Blood. 2017 Mar 30; 129(13):1791-1801.
    View in: PubMed
    Score: 0.174
  4. Individualized vaccination of AML patients in remission is associated with induction of antileukemia immunity and prolonged remissions. Sci Transl Med. 2016 12 07; 8(368):368ra171.
    View in: PubMed
    Score: 0.172
  5. Mucin 1 is a potential therapeutic target in cutaneous T-cell lymphoma. Blood. 2015 Jul 16; 126(3):354-62.
    View in: PubMed
    Score: 0.155
  6. Yttrium-90 ibritumomab tiuxetan followed by rituximab maintenance as treatment for patients with diffuse large B-cell lymphoma are not candidates for autologous stem cell transplant. Acta Haematol. 2015; 133(4):347-53.
    View in: PubMed
    Score: 0.152
  7. MUC1 is a potential target for the treatment of acute myeloid leukemia stem cells. Cancer Res. 2013 Sep 01; 73(17):5569-79.
    View in: PubMed
    Score: 0.136
  8. Vaccination with dendritic cell/tumor fusions following autologous stem cell transplant induces immunologic and clinical responses in multiple myeloma patients. Clin Cancer Res. 2013 Jul 01; 19(13):3640-8.
    View in: PubMed
    Score: 0.135
  9. Lenalidomide enhances anti-myeloma cellular immunity. Cancer Immunol Immunother. 2013 Jan; 62(1):39-49.
    View in: PubMed
    Score: 0.126
  10. PD-1 blockade by CT-011, anti-PD-1 antibody, enhances ex vivo T-cell responses to autologous dendritic cell/myeloma fusion vaccine. J Immunother. 2011 Jun; 34(5):409-18.
    View in: PubMed
    Score: 0.117
  11. Vaccination with dendritic cell/tumor fusion cells results in cellular and humoral antitumor immune responses in patients with multiple myeloma. Blood. 2011 Jan 13; 117(2):393-402.
    View in: PubMed
    Score: 0.113
  12. Generation of tumor-specific T lymphocytes using dendritic cell/tumor fusions and anti-CD3/CD28. J Immunother. 2010 Feb-Mar; 33(2):155-66.
    View in: PubMed
    Score: 0.107
  13. Immunomodulatory effects of vitamin D: implications for GVHD. Bone Marrow Transplant. 2010 Sep; 45(9):1463-8.
    View in: PubMed
    Score: 0.107
  14. Leukemia derived dendritic cells (LDCs) may be ineffective as a cancer vaccine for acute myeloid leukemia (AML). J Clin Oncol. 2005 Jun; 23(16_suppl):2527.
    View in: PubMed
    Score: 0.077
  15. Immune reconstitution following high-dose chemotherapy with stem cell rescue in patients with advanced breast cancer. Bone Marrow Transplant. 2000 Jul; 26(2):169-76.
    View in: PubMed
    Score: 0.055
  16. Selective in vivo mobilization with granulocyte macrophage colony-stimulating factor (GM-CSF)/granulocyte-CSF as compared to G-CSF alone of dendritic cell progenitors from peripheral blood progenitor cells in patients with advanced breast cancer undergoing autologous transplantation. Clin Cancer Res. 1999 Oct; 5(10):2735-41.
    View in: PubMed
    Score: 0.052
  17. Brentuximab vedotin, doxorubicin, vinblastine, and dacarbazine for nonbulky limited-stage classical Hodgkin lymphoma. Blood. 2019 08 15; 134(7):606-613.
    View in: PubMed
    Score: 0.051
  18. Phase 1 clinical trial evaluating abatacept in patients with steroid-refractory chronic graft-versus-host disease. Blood. 2018 06 21; 131(25):2836-2845.
    View in: PubMed
    Score: 0.047
  19. Cabozantinib is well tolerated in acute myeloid leukemia and effectively inhibits the resistance-conferring FLT3/tyrosine kinase domain/F691 mutation. Cancer. 2018 01 15; 124(2):306-314.
    View in: PubMed
    Score: 0.046
  20. Sequential infusion of donor-derived dendritic cells with donor lymphocyte infusion for relapsed hematologic cancers after allogeneic hematopoietic stem cell transplantation. Am J Hematol. 2014 Dec; 89(12):1092-6.
    View in: PubMed
    Score: 0.037
  21. Interleukin-2 and regulatory T cells in graft-versus-host disease. N Engl J Med. 2011 Dec 01; 365(22):2055-66.
    View in: PubMed
    Score: 0.030
  22. Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma. Blood. 2010 Aug 05; 116(5):679-86.
    View in: PubMed
    Score: 0.027
  23. Peripheral blood progenitor cell product contains Th1-biased noninvariant CD1d-reactive natural killer T cells: implications for posttransplant survival. Exp Hematol. 2008 Apr; 36(4):464-72.
    View in: PubMed
    Score: 0.023
  24. Protective antibody responses to pneumococcal conjugate vaccine after autologous hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2005 Mar; 11(3):213-22.
    View in: PubMed
    Score: 0.019
  25. The impact of induction duration and the number of high-dose cycles on the long-term survival of women with metastatic breast cancer treated with high-dose chemotherapy with stem cell rescue: an analysis of sequential phase I/II trials from the Dana-Farber/Beth Israel STAMP program. Biol Blood Marrow Transplant. 2002; 8(4):198-205.
    View in: PubMed
    Score: 0.015
  26. A major fraction of human bone marrow lymphocytes are Th2-like CD1d-reactive T cells that can suppress mixed lymphocyte responses. J Immunol. 2001 Nov 15; 167(10):5531-4.
    View in: PubMed
    Score: 0.015
  27. A short course of induction chemotherapy followed by two cycles of high-dose chemotherapy with stem cell rescue for chemotherapy naive metastatic breast cancer: sequential phase I/II studies. Bone Marrow Transplant. 2001 Sep; 28(5):447-54.
    View in: PubMed
    Score: 0.015
  28. A short course of induction chemotherapy followed by two cycles of high-dose chemotherapy with stem cell rescue for chemotherapy naive metastatic breast cancer. Bone Marrow Transplant. 2001 Feb; 27(3):269-78.
    View in: PubMed
    Score: 0.014
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.